EngiChem Lifesciences (CEO Ki-Young Son) announced on the 11th that it has organized a team for full-scale AI-based new drug development starting in late 2024 and has begun developing an innovative 'anti-aging new drug' that effectively removes aging cells.
Starting with the discovery of a number of small-molecule compounds that reverse aging through AI-based structural analysis, EngiChem Lifesciences plans to optimize leading compounds by early 2026, secure IP and license them out, and develop an AI new drug development platform for the mechanism of removing senescent cells.
EngiChem Life Sciences has focused on developing innovative anti-inflammatory and anti-cancer treatments to address unmet medical needs, and has been conducting continuous non-clinical and clinical development to enhance its new drug development and commercialization capabilities. In addition, it is solidifying its position as a new drug development company based on its excellent research capabilities and technological competitiveness accumulated in the anti-inflammatory and anti-cancer fields.
Now, based on its new drug development capabilities, Enzychem Lifesciences will develop an innovative anti-aging new drug that effectively removes senescent cells. Enzychem Lifesciences has completed target selection by utilizing its molecular cell research capabilities acquired through anti-inflammation and anti-cancer research, and is currently using commercialized software to select target molecules closely related to the removal of senescent cells and discover anti-aging new drug substances.
The substance is a mechanism for removing senescent cells, which are the main cause of various aging-related diseases, and is commonly effective in various diseases and can be widely applied. In addition, in terms of research efficiency, based on a detailed understanding of the drug's mechanism of action, we plan to reduce the time and cost required for discovering new drugs by using AI models more efficiently to make accurate predictions.
Starting in late 2024, EngiChem Life Sciences will organize a team for AI-based new drug development and establish a synthesis facility to discover anti-aging small-molecule compounds through AI-based structural analysis. In addition, it has already secured a number of effective substances that are expected to show better efficacy than new drug substances under development by other companies, and is currently deriving leading substances.
An official from EngiChem Life Sciences said, “We plan to complete the optimization of the lead substance by early 2026 and pursue IP acquisition and licensing out. We plan to actively lead the formation of a reverse aging research network, and in terms of utilizing AI, we will appropriately use our own team and outsourcing to shorten the time required for substance discovery and non-clinical development by less than 50% and quickly achieve milestones.”
He continued, “In the future, we will establish a panel of biomarkers related to aging, develop an AI new drug development platform utilizing various targets, and build a system that can continuously secure small molecule new drugs with a mechanism for removing senescent cells. Furthermore, we plan to complete technological differentiation and achieve the goal of developing personalized anti-aging new drugs.”
- See more related articles
You must be logged in to post a comment.